TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06004271

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Exercise protocol:~Progressive Resistance Exercise Training Bridge exercise sit-up exercise functional walking exercise Stretching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Exercise protocol:~Progressive Resistance Exercise Training Bridge exercise sit-up exercise functional walking exercise Stretching

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercise
Description: Exercise protocol:~Progressive Resistance Exercise Training Bridge exercise sit-up exercise functional walking exercise Stretching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and taping
Description: When applying kinesiology taping to the gluteus medius, first of all, for its anterior fiber, the tape portion will be attached lateral to the Spina iliaca anterior superior by giving a slight slope downwards from the crista iliaca with 50-75% tension. For the posterior fiber; Starting from the trochanter major, 50-75% tension will be applied along the muscle fiber.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: In the placebo tape application, the kinesiological tappings will be adhered horizontally without tension along the long line of the Tensor facie late muscle. The application to the ankle will be attached horizontally, without tension, slightly above the lateral malleolus.
Study: NCT05048043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted Behavior Intervention
Description: The CABI includes a serious game called ATHEMOS that is designed to help students rehearse skills that ameliorate impairments associated with ADHD, including organization, scheduling, and note taking strategies. Once students have some experience with the game, a teacher consultee will help students actively transfer skills learned in the game to real-world classroom demands.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Challenging Horizons Program
Description: The Challenging Horizons Program is an established psychosocial intervention package for young adolescents with ADHD, focusing on academic and behavioral impairments.
Study: NCT05930483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Use Fitbit scale and Fitbit Luxe (or latest model)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Use Fitbit scale and Fitbit Luxe (or latest model)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Use Fitbit scale and Fitbit Luxe (or latest model)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Use Fitbit scale and Fitbit Luxe (or latest model)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Use Fitbit scale and Fitbit Luxe (or latest model)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Use Cook for Your Life website

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Use Cook for Your Life website

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Use Cook for Your Life website

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Use Cook for Your Life website

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Use Cook for Your Life website

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Use Cook for Your Life website

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04487808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pecan
Description: Unsalted raw pecans incorporated in snack and meal recipes as part of a dietary pattern

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pecan
Description: Unsalted raw pecans incorporated in snack and meal recipes as part of a dietary pattern

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Average American Diet devoid of nuts
Description: Diet mimicking usual American intake
Study: NCT05930483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Participate in individualized health coaching sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Participate in individualized health coaching sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Participate in individualized health coaching sessions
Study: NCT06292351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMB-I (Dimebon)
Description: 20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMB-I (Dimebon)
Description: 20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
Study: NCT04617678

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation Program
Description: We will assess whether prehabilitation intervention helps mitigate adverse symptoms (e.g., anxiety, depression, suicidality, distress, nutritional status, dysphagia, sarcopenia, and well-being) on a sample of head and neck cancer patients. Subjects will attend a Prepare for Surgery Heal Faster session and meet with a physical therapist, registered dietician, speech language pathologist, and masters of social work at pre-treatment, 6-8 weeks post-treatment, and 5-6 months post-treatment completion.
Study: NCT05746169

Intervention type: OTHER
Intervention: Health Questionnaires
Description: A questionnaire with content developed and tested in the investigator's previous reproductive and cancer epidemiology studies as part of the NIH Environmental Influences on Child Health Outcomes (ECHO) consortium will be used to collect information on primary established and hypothesized risk factors for cancer and additional covariates.

Intervention type: OTHER
Intervention: Specimen sample collection
Description: Collection of blood, urine, nails, hair, and saliva samples will be obtained during the participant encounters.
Study: NCT05382299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously
Study: NCT06543303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTV100 Low dose
Description: 1% Cevimeline Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTV100 Mid dose
Description: 2% Cevimeline Ophthalmic Solution
Study: NCT05888298

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Greater occipital nerve radiofrequency
Description: Greater nerve block and radiofrequency will be performed at the C2 vertebra level or occipital protuberance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greater occipital nerve radiofrequency
Description: Greater nerve block and radiofrequency will be performed at the C2 vertebra level or occipital protuberance
Study: NCT04868773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Oral cabozantinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Oral TAS-102 (trifluridine and tipiracil)
Study: NCT06543303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTV100 High dose
Description: 4% Cevimeline Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06560502

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care-DFU
Description: Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 13 weeks, whichever occurs first.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AmnioCore - DFU
Description: Participants will receive weekly applications of AmnioCore and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
Study: NCT04932096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin
Description: melatonin supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: microcrystalline cellulose filled capsule
Study: NCT06560502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amnio Quad-Core - DFU
Description: Participants will receive weekly applications of Amnio Quad-Core and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
Study: NCT05678439

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sesame extract
Description: At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of sesame extract (sesamin 37-56mg per capsule). The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: At the treatment period (0th to 8th week of the experiment), participants with sleeping disorder will receive 2 capsules of placebo. The 8th to 9th week will be the washout period. The placebo group and sesame extract group will be cross-over at 10th week to 18th week of the experiment.
Study: NCT05004792

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DermLoop Learn
Description: DermLoop Learn is our AI-augmented digital educational platform with case training on a library of 18,000+ benign and malignant skin lesions, educational videos on the correlation between dermoscopy and histology, as well as written learning modules for the most common skin lesion diagnosis. The education platform will give the user feedback on the image-based case training in dermoscopic diagnostic accuracy and adjust the cases depending on the user's progression.
Study: NCT06560502

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care-VLU
Description: Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and compression) until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
Study: NCT06167785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg intravenously every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib 160 mg oral twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + Zanubrutinib
Description: Tislelizumab 200mg intravenously day 1 of each cycle every 3 weeks + Zanubrutinib 160 mg oral twice daily starts day 1 of each cycle
Study: NCT04883151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOFUS pilot program
Description: The SOFUS pilot program consists of six pre-loss sessions (Program 1) and a further six post-loss sessions (Program 2), which are delivered over a 3-month period. Each session ranges from 1-1.5 hours. Sessions 1 and 6 includes the whole family, sessions 2 and 3 focus on the parents, while sessions 4 and 5 target the children (with parents if the child is \<10 years old).~SOFUS consists of three primary components: i) strengthening COMMUNICATION between parents and children, ii) NORMALIZATION of grief processes (pre and post-lost), and iii) EMOTION REGULATION strategies targeting motivational awareness and regulatory skills in grief management (pre and post-lost).~Families in Program 1 may be offered Program 2 if the child dies before the entire program has been delivered.
Study: NCT05060991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduction in antimetabolite immunosuppression
Description: Reduction in dose in mycophenolate mofetil/mycophenolic acid (MMF) or azathioprine before and after receiving 3rd dose vaccination
Study: NCT06447701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Single dose intravenous application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9% 100ml
Description: Single dose intravenous application
Study: NCT04178408

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06355375

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise in pregnancy
Description: aerobic exercise
Study: NCT05383417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoClip
Description: Clip attached to mid portion of the endotracheal tube.
Study: NCT04874818

Intervention type: DIAGNOSTIC_TEST
Intervention: [89Zr]Df-IAB22M2C PET/CT scan
Description: PET imaging procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: [89Zr]Df-IAB22M2C PET/CT scan
Description: PET imaging procedure
Study: NCT06560502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amnio Tri-Core - VLU
Description: Participants will receive weekly applications of Amnio Tri-Core and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AmnioCore Pro
Description: Participants will receive weekly applications of AmnioCore Pro and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amniocore Pro +
Description: Participants will receive weekly applications of Amniocore Pro + and Standard of Care until ulcer closure, or a maximum of 13 weeks, whichever occurs first.
Study: NCT06293053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Injection solution~Route of administration: Subcutaneous
Study: NCT05073120

Intervention type: OTHER
Intervention: Piqray Prescriber's/HCP guide for hyperglycemia
Description: oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA will be provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aims to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.
Study: NCT04993079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clotild®
Description: Use of Clotild® as neurovascular guidewire
Study: NCT04758390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMARA (intervention group)
Description: The IMARA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
Study: NCT04799262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 MG
Description: Oral tofacitinib at the dose of 5mg twice a day was given for 24 weeks. Prednisone (or equivalent oral GCs) of 15 mg daily at baseline willed be tapered to 2.5 mg or less within 20 weeks. Unless specifically considered by patients and physicians, the GC will be tapered followed the predefined taper regimen depending on the response to treatment judged by PMR-AS. The PMR-AS will be determined every two weeks; if\<10 the daily GC dosage was decreased by 2.5mg; if\>17, the GC daily dosage was increased to the previous dosage; if 10≤PMR-AS≤17, the GC daily dosage was maintained at the previous stable dose.
Study: NCT04758390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promotion control group
Description: The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
Study: NCT06299124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT-419B
Description: RGT-419B will be administered orally
Study: NCT06419660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 300202
Description: BI 300202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 300202
Description: BI 300202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: esomeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: esomeprazole
Study: NCT06418061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI3005
Description: Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)
Study: NCT04674969

Intervention type: DEVICE
Intervention: Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.
Description: Ranger™ Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter; ELUVIA™ Drug-Eluting Vascular Stent System
Study: NCT05503459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicycle learning
Description: The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), bicycle learning (40 min), and cool-down (10 min). In the bicycle training activity, participants were asked to ride on a training bicycle with training wheels to gain better control of the bike in a gradual way. Participants then progressed from the training bicycle to a two-wheel bicycle. To keep participants on the learning curve, they were asked to ride through an obstacle course that was progressively more difficult to negotiate. The obstacles were designed by a focus group, which consisted of four physical education teachers from participating schools and one experienced cycling coach with more than five years of coaching experience.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stationary cycling
Description: The 10 intervention sessions were conducted in an identical format, comprising three activities: warm-up (10 min), stationary cycling (40 min), and cool-down (10 min). For stationary cycling activity, they were also asked every 10 mins during exercise to indicate their ratings of perceived exertion (target range: 3-5). Participants were positively reinforced verbally with compliments for their efforts in the training program and their daily improvements were visualized through graphs kept in the child's home.
Study: NCT04559646

Intervention type: PROCEDURE
Intervention: Pacemaker implantation
Description: Implantation of the pacemaker due to indications in patients with atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other.

Intervention type: PROCEDURE
Intervention: Pacemaker implantation
Description: Implantation of the pacemaker due to indications in patients with atrioventricular block, sick sinus syndrome, atrial fibrillation with impaired atrioventricular conduction or other.

Intervention type: DRUG
Intervention: Haemostatic solution Haemoblock application
Description: Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation.

Intervention type: DRUG
Intervention: Saline solution application
Description: Saline solution will be used after pocket formation during pacemaker implantation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound of pacemaker pocket
Description: Pacemaker pocket ultrasound examination to diagnose pocket hematoma 3-5 days after surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound of pacemaker pocket
Description: Pacemaker pocket ultrasound examination to diagnose pocket hematoma 3-5 days after surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling for Platelet, Prothrombin, Fibrinogen, International Normalized Ratio, Creatinine, Albumin evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling for Platelet, Prothrombin, Fibrinogen, International Normalized Ratio, Creatinine, Albumin evaluation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Heart ultrasound examination for left ventricular ejection fraction measurement.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Heart ultrasound examination for left ventricular ejection fraction measurement.
Study: NCT05434663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUSTOL
Description: SUSTOL 10 mg Subcutaneous (SC) on Day 1 of up to 4 cycles.
Study: NCT05448378

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol
Description: D-chiro-inositol 600 mg twice per day on an empty stomach for one month